Startups
Neurimmune is a biopharmaceutical company translating human immune memory into antibody therapeutics. Neurimmune discovered aducanumab for Alzheimer's disease together with a team of researchers at the University of Zurich and licensed it to Biogen.
Neurimmune's Reverse Translational Medicine technology platform translates the genetic information from human white blood cells into selective high-affinity antibody drug candidates. Besides aducanumab, Neurimmune discovered cinpanemab for Parkinson's disease, the anti-tau antibody BIIB076 for Alzheimer's disease, the anti-miSOD1 antibody AP-101 for amyotrophic lateral sclerosis, and the anti-ATTR antibody NI006 for cardiomyopathy. These programs are currently evaluated in clinical trials.
Neurimmune's Reverse Translational Medicine technology platform translates the genetic information from human white blood cells into selective high-affinity antibody drug candidates. Besides aducanumab, Neurimmune discovered cinpanemab for Parkinson's disease, the anti-tau antibody BIIB076 for Alzheimer's disease, the anti-miSOD1 antibody AP-101 for amyotrophic lateral sclerosis, and the anti-ATTR antibody NI006 for cardiomyopathy. These programs are currently evaluated in clinical trials.
Overview
Location
Switzerland
Employees
51-200
Total raised
$150M
Founded date
2006
Investors 1
| Date | Name | Website |
| Sign up to see | Sign up to see | Sign up to see |
Funding Rounds 1
| Date | Series | Amount | Investors |
| Sign up to see | Sign up to see | Sign up to see | Sign up to see |
Mentions in press and media 29
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Sep 2, 2026 | NovaGo Secures USD 30 Million to Advance Proof-of-Concept Study in Acute Spinal Cord Injury | Spinal cord injury remains an area of high unmet medical need. There are currently no approved regenerative treatment options that restore lost neurological function, leaving patients and their families with limited therapeutic prospects f... |
| Jul 22, 2026 | Neurimmune closes licensing deal of up to USD425 million | Cliramitug is an investigational human monoclonal antibody discovered by Neurimmune and designed to deplete amyloid deposits from affected hearts in patients with amyloid transthyretin cardiomyopathy (ATTR-CM). In 2022, Neurimmune entered ... |
| Dec 5, 2025 | Neurimmune to receive up to $780m in extended partnership with AstraZeneca | Neurimmune is a clinical stage biopharmaceutical company building next generation therapeutics to address protein aggregation diseases with extensive experience in amyloid depletion. Their drug candidate N1009 is a preclinical human monocl... |
| Oct 18, 2024 | Positive progress in addressing unmet medical needs | The FDA has granted Fast Track designation to Neurimmune’s partner Alexion, AstraZeneca Rare Disease Fast Track designation for the development of ALXN2220 (formerly NI006) for the treatment of transthyretin amyloidosis with cardiomyopathy... |
| Jul 30, 2024 | Is it worth spending RMB 200,000 a year to delay the onset of Alzheimer’s disease? | The loss of control can strike out of the blue, even when preceded by minor symptoms. When Zhang Li’s mother began experiencing symptoms like dizziness and poor memory, it was initially dismissed as a mild stroke—a minor ailment. However, o... |
| Apr 9, 2024 | Clinical success for Neurimmune | Transthyretin-mediated amyloid cardiomyopathy (ATTR-CM) is an underdiagnosed, systemic clinical condition that leads to progressive heart failure and high rate of fatality within four years from diagnosis. Despite recent advances in slowin... |
| Feb 2, 2024 | Biogen returns global IP rights on Alzheimer’s drug to Neurimmune | Neurimmune is a clinical-stage biotech company that develops drug candidates for the Central Nervous System (CNS) and related protein aggregation diseases, including Alzheimer’s and Parkinson’s disease. One of its discoveries was ADUHELM (... |
| May 30, 2023 | Positive results for Swiss biotechs’ clinical studies | |
| Jan 17, 2022 | Neurimmune and Ono Pharmaceutical collaborate in the field of neurodegenerative diseases |
Show more
Reviews 0
FAQ about Neurimmune AG
When was Neurimmune AG founded?
Neurimmune AG was founded in 2006.
How much funding has Neurimmune AG raised?
Neurimmune AG has raised $150M in total across 1 funding round.
What has the press written about Neurimmune AG?
Parsers VC has collected 29 articles mentioning Neurimmune AG, among them “NovaGo Secures USD 30 Million to Advance Proof-of-Concept Study in Acute Spinal Cord Injury” (Sep 2, 2026) and “Neurimmune closes licensing deal of up to USD425 million” (Jul 22, 2026).
Is Neurimmune AG still active?
Yes, Neurimmune AG is active; its latest activity on Parsers VC dates from Sep 18, 2026.